Abstract
We used high-resolution mass spectrometry to map the cytotoxic T lymphocyte (CTL) proteome and the effect of the metabolic checkpoint kinase mTORC1 on CTLs. The CTL proteome was dominated by metabolic regulators and granzymes, and mTORC1 selectively repressed and promoted expression of a subset of CTL proteins (~10%). These included key CTL effector molecules, signaling proteins and a subset of metabolic enzymes. Proteomic data highlighted the potential for negative control of the production of phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P3) by mTORC1 in CTLs. mTORC1 repressed PtdIns(3,4,5)P3 production and determined the requirement for mTORC2 in activation of the kinase Akt. Our unbiased proteomic analysis thus provides comprehensive understanding of CTL identity and the control of CTL function by mTORC1.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Heng, T.S.P. & Painter, M.W. The Immunological Genome Project: networks of gene expression in immune cells. Nat. Immunol. 9, 1091–1094 (2008).
Schwanhäusser, B. et al. Global quantification of mammalian gene expression control. Nature 473, 337–342 (2011).
Ly, T. et al. A proteomic chronology of gene expression through the cell cycle in human myeloid leukemia cells. eLife 3, e01630 (2014).
Larance, M. & Lamond, A.I. Multidimensional proteomics for cell biology. Nat. Rev. Mol. Cell Biol. 16, 269–280 (2015).
Geiger, T., Wehner, A., Schaab, C., Cox, J. & Mann, M. Comparative proteomic analysis of eleven common cell lines reveals ubiquitous but varying expression of most proteins. Mol. Cell. Proteomics 11, M111.014050 (2012).
Sinclair, L.V. et al. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat. Immunol. 9, 513–521 (2008).
Araki, K. et al. mTOR regulates memory CD8 T-cell differentiation. Nature 460, 108–112 (2009).
Pollizzi, K.N. et al. mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation. J. Clin. Invest. 125, 2090–2108 (2015).
Hara, K. et al. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J. Biol. Chem. 273, 14484–14494 (1998).
Thoreen, C.C. et al. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485, 109–113 (2012).
Düvel, K. et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39, 171–183 (2010).
Kidani, Y. et al. Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. Nat. Immunol. 14, 489–499 (2013).
Finlay, D.K. et al. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J. Exp. Med. 209, 2441–2453 (2012).
Yu, Y. et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322–1326 (2011).
Hsu, P.P. et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317–1322 (2011).
Harrington, L.S. et al. The TSC1–2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166, 213–223 (2004).
Wisś niewski, J.R., Hein, M.Y., Cox, J. & Mann, M.A. 'proteomic ruler' for protein copy number and concentration estimation without spike-in standards. Mol. Cell. Proteomics 13, 3497–3506 (2014).
Pearce, E.L. & Pearce, E.J. Metabolic pathways in immune cell activation and quiescence. Immunity 38, 633–643 (2013).
Sinclair, L.V. et al. Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat. Immunol. 14, 500–508 (2013).
Jacobs, S.R. et al. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J. Immunol. 180, 4476–4486 (2008).
Macintyre, A.N. et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 20, 61–72 (2014).
Simpson, I.A. et al. The facilitative glucose transporter GLUT3: 20 years of distinction. Am. J. Physiol. Endocrinol. Metab. 295, E242–E253 (2008).
Smith, K.A. & Cantrell, D.A. Interleukin 2 regulates its own receptors. Proc. Natl. Acad. Sci. USA 82, 864–868 (1985).
Feinerman, O. et al. Single-cell quantification of IL-2 response by effector and regulatory T cells reveals critical plasticity in immune response. Mol. Syst. Biol. 6, 437 (2010).
Best, J.A. et al. Transcriptional insights into the CD8+ T cell response to infection and memory T cell formation. Nat. Immunol. 14, 404–412 (2013).
García-Martínez, J.M. et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 421, 29–42 (2009).
Rao, R.R., Li, Q., Bupp, M.R.G. & Shrikant, P.A. Transcription factor Foxo1 represses T-bet-mediated effector functions and promotes memory CD8+ T cell differentiation. Immunity 36, 374–387 (2012).
Nakaya, M. et al. Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. Immunity 40, 692–705 (2014).
van der Windt, G.J.W. et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 36, 68–78 (2012).
Alessi, D.R. et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr. Biol. 7, 261–269 (1997).
Barnett, S.F. et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 385, 399–408 (2005).
Sarbassov, D.D., Guertin, D.A., Ali, S.M. & Sabatini, D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098–1101 (2005).
Biondi, R.M., Kieloch, A., Currie, R.A., Deak, M. & Alessi, D.R. The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB. EMBO J. 20, 4380–4390 (2001).
Delgoffe, G.M. et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 12, 295–303 (2011).
Najafov, A., Shpiro, N. & Alessi, D.R. Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors. Biochem. J. 448, 285–295 (2012).
Waugh, C., Sinclair, L., Finlay, D., Bayascas, J.R. & Cantrell, D. Phosphoinositide (3,4,5)-triphosphate binding to phosphoinositide-dependent kinase 1 regulates a protein kinase B/Akt signaling threshold that dictates T-cell migration, not proliferation. Mol. Cell. Biol. 29, 5952–5962 (2009).
Macintyre, A.N. et al. Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity 34, 224–236 (2011).
Yang, P., Li, Z., Fu, R., Wu, H. & Li, Z. Pyruvate kinase M2 facilitates colon cancer cell migration via the modulation of STAT3 signalling. Cell. Signal. 26, 1853–1862 (2014).
Palsson-McDermott, E.M. et al. Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages. Cell Metab. 21, 65–80 (2015).
Angulo, I. et al. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science 342, 866–871 (2013).
Lucas, C.L. et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat. Immunol. 15, 88–97 (2014).
Pircher, H., Bürki, K., Lang, R., Hengartner, H. & Zinkernagel, R.M. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 342, 559–561 (1989).
Wang, R. et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35, 871–882 (2011).
Clark, J. et al. Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry. Nat. Methods 8, 267–272 (2011).
Navarro, M.N., Goebel, J., Feijoo-Carnero, C., Morrice, N. & Cantrell, D.A. Phosphoproteomic analysis reveals an intrinsic pathway for the regulation of histone deacetylase 7 that controls the function of cytotoxic T lymphocytes. Nat. Immunol. 12, 352–361 (2011).
Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372 (2008).
Cox, J. et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell. Proteomics 13, 2513–2526 (2014).
Da Huang, W., Sherman, B.T. & Lempicki, R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 37, 1–13 (2009).
Saeed, A.I. et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34, 374–378 (2003).
Acknowledgements
We thank past and present colleagues of the Cantrell Group for advice and discussions; C. Feijoo-Carnero for help with microarray analysis; T. Ly for help with peptide fractionation using hSAX; and D. Lamont and the team of the MS facility at the College of Life Sciences of the University of Dundee and the Finnish DNA microarray Centre at the Centre for Biotechnology (Turku, Finland). Supported by the Wellcome Trust (093713/Z/10/A to J.L.H., 073980/Z/03/Z and 105024/Z/14/Z to A.I.L., 065975/Z/01/A and 097418/Z/11/Z to D.A.C.).
Author information
Authors and Affiliations
Contributions
J.L.H., design and performance of proteomic and transcriptomic experiments and most other experiments; K.E.A., measurement of PtdIns(3,4,5)P3; L.V.S., glucose uptake assay; K.M.G., lactate output assay; A.B.M., Encyclopedia of Proteome Dynamics; P.T.H. and L.R.S., experimental design for measurement of PtdIns(3,4,5)P3; A.I.L., experimental design; D.A.C., experimental design and manuscript authorship (with input from J.L.H.).
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Integrated supplementary information
Supplementary Figure 1 Experimental design for analysis of the CTL proteome.
Splenocytes from P14 TCR transgenic mice were activated for 48 h with gp33 in the presence of IL-2 and IL-12. Cells were expanded in IL-2/IL-12 for 4 days. CTL were lysed in urea buffer and digested with either lysyl endopeptidase (LysC) or combined LysC and trypsin and subjected to SAX chromatography prior to Orbitrap mass spectrometer analysis. Andromeda and MaxQuant were used for data normalisation, peak picking, database searching, peptide and protein identification. Further analysis was done using R, Perseus, Excel.
Supplementary Figure 2 Glutaminolysis in CTLs.
Representation of the glutaminolytic pathway: enzymes catalyzing glutaminolytic reactions in purple, metabolic intermediates in black. Glutamate dehydrogenase (GLUD1) as rate limiting step highlighted.
Supplementary Figure 3 Modes of Akt activation in CTLs.
Different mechanisms of Akt activation. Low PtdIns(3,4,5)P3 (PIP3) levels in the plasma membrane cause Akt to be locked in an inactive state. IL-2 receptor and nutrient signaling in CTL maintain basal PI(3)K and mTOR signaling and thus enable the PIF-pocket dependent activation of membrane-bound Akt via its upstream kinase PDK1. Acute mTOR inhibition leads to dephosphorylation of Akt p-S473 and thus disrupts the colocalisation of Akt and PDK1 via p-S473-PIF-pocket interaction. Chronic mTOR inhibition leads to the accumulation of PtdIns(3,4,5)P3 and allows colocalisation of Akt and PDK1 via their respective PH domains and subsequent activation of Akt via T308 phosphorylation regardless of dephosphorylation of Akt p-S473.
Supplementary Figure 4 Effects of treatment with rapamycin or KU-0063794 on the CTL proteome.
Scatter plot depicting correlation of mean fold changes in protein expression of DMSO (vehicle) treated CTL vs CTL treated with rapamycin (x-axis) or KU-0063794 (y-axis) obtained by stable isotope labelling of amino acid in cell culture (SILAC) based proteomics. 4934 rapamycin:DMSO vs KU-0063794:DMSO pairs are plotted. Statistically different proteins (p ≤ 0.01, p-value determined by unpaired, two-tailed, unequal variance t-test on SILAC ratios) are depicted as filled black circles. All proteins with p ≤ 0.01 show a less than 2-fold difference between the inhibitor induced effects (area within the two dashed diagonal lines). Furthermore, when compared to control CTL, all of these proteins show a less than 2-fold up or down-regulation with either rapamycin (area between the two dashed vertical lines) or KU-0063794 (area between the two horizontal dashed lines).
Supplementary Figure 5 Encyclopedia of Proteome Dynamics web-based data-sharing tool.
Screen shots of several sections of the EPD (http://www.peptracker.com/epd). (a) Homepage with search input accepting Uniprot accession, gene term, protein description, protein name or gene ontology terms. (b) Data derived from multiple databases such as Uniprot or STRING (e.g. in this case for perforin) are displayed with links to these and further external resources. (c) Histogram showing mean estimated copy numbers of the selected protein (as calculated by the proteomic ruler) highlighted in the context of the copy numbers distribution of the entire dataset. (d) Volcano plot for the 48h rapamycin treated CTL. The mean fold change for the selected protein is highlighted in the volcano plot and shown in the context of all protein groups of the dataset.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–5 (PDF 2844 kb)
Rights and permissions
About this article
Cite this article
Hukelmann, J., Anderson, K., Sinclair, L. et al. The cytotoxic T cell proteome and its shaping by the kinase mTOR. Nat Immunol 17, 104–112 (2016). https://doi.org/10.1038/ni.3314
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ni.3314
This article is cited by
-
VEGF-A enhances the cytotoxic function of CD4+ cytotoxic T cells via the VEGF-receptor 1/VEGF-receptor 2/AKT/mTOR pathway
Journal of Translational Medicine (2023)
-
The potential role of the pseudobranch of molly fish (Poecilia sphenops) in immunity and cell regeneration
Scientific Reports (2023)
-
The Immunological Proteome Resource
Nature Immunology (2023)
-
Lipid metabolic features of T cells in the Tumor Microenvironment
Lipids in Health and Disease (2022)
-
Protein synthesis, degradation, and energy metabolism in T cell immunity
Cellular & Molecular Immunology (2022)